Press Releases

09 January 2024

 

 

 

Agreement with Alcyon Italia for the distribution of BIOCERA-VET® product line in Italy

 

 

 

04 January 2024

 

 

 

TheraVet reports significant success of its the last educational webinar on canine osteosarcoma co-organized with Veterinary Instrumentation (UK)

 

 

 

6 December 2023

 

 

 

TheraVet reports further achievements on its Osteosarcoma Program

 

 

 

23 November 2023 

 

 

 

 

Launch of BIOCERA-VET® Canine Osteosarcoma Study conducted by the prestigious University of Florida

 

 

08 November 2023

 

 

 

Significant Sales Progression for BIOCERA-VET® in Q3 2023

 

 

 

25 October 2023

 

 

 

TheraVet announces the appointment of a Chief Financial Officer to reinforce its global financing and cost control strategy

 

 

 

18 October 2023 

 

 

 

Increasingly successful attendance in major ortho EU & US conferences and North America launch of BIOCERA-VET COMBO-CLEAN

 

 

 

11 October 2023

 

 


BIOCERA-VET in Horse Bone Cysts Highlighted at an International Equine Conference in the USA

 

 

 

27 September 2023

 

 

 

Patient recruitment phase successfully completed in BIOCERA-VET fracture revision surgery study in toy dogs

 

 

11 July 2023

 

 

 

 

TheraVet provides an update on its 2023 half-year development and portfolio strategy

 

 

 

 

15 June 2023 

 

 

 

TheraVet announces 300% increase in participating Centers in the Osteosarcoma Program since its initiation 6 months ago

 

 

 

31 May 2023 

 

 

 

TheraVet announces the commercial launch of a local and sustained antibiotic releasing bone substitute

 

 

 

04 May 2023

 

 

 

TheraVet continues the assessment of BIOCERA-VET in a new clinical program

 

 

 

06 April 2023

 

 

 

TheraVet launches its Osteosarcoma Reference Centers program

 

 

 

21 February 2023 

 

 

 

TheraVet signs an international distribution agreement for BIOCERA-VET® covering 24 countries

 

 

 

15 January 2023

 

 

 

TheraVet announces the start of the assessment of BIOCERA-VET® in horse bone cyst

 

 

 

12 December 2022

 

 

 

TheraVet optimizes its commercial strategy in France with a new distribution agreement for its BIOCERA-VET® range

 


7 December 2022

 

 


BIOCERA-VET® nominated for the Veterinary Innovation Award (AFVAC 2022)

 

 


English

 

 

 

26 September 2022

 

 

 

TheraVet announces an exclusive distribution agreement for BIOCERA-VET® in the USA

 

 

 

19 September 2022

 

 

 

TheraVet announces its participation in the 2022 ESVOT Congress with 3 scientific communications

 

 

 

09 September 2022

 

 


TheraVet reports its 2022 half-year results and provides an update on the development of its activities

 


1 July 2022

 

 

TheraVet provides its 2022 first half-year operational update

 


30 June 2022

 

 

 

TheraVet annonces the commercial launch of its BIOCERA-VET product line in the United States of America

 

 

 

30 May 2022

 

 

 

TheraVet signs a distribution agreement with Nuzoa, a leading Spanish company in the distribution of veterinary products and services

 

 

 

English - Français - Dutch

 

 

 

10 May 2022

 

 

 

TheraVet signs an important distribution agreement with the orthopaedics & surgical instrumentation distributor, Veterinary Instrumentation

 

 

English - Français - Dutch

 

 

 

15 March 2022

 

 


Commercial launch of BIOCERA-VET® in United Kingdom and Ireland

 

 

 

English Français - Dutch

 

 


07 February 2022

 

 

 

TheraVet broadens its bone substitutes portfolio with an innovative line of biological bone grafts

 

 

 

04  February  2022

 

 

 

Positive results of BIOCERA-VET®-Bone Surgery presented at the Annual Conference of the US Veterinary Orthopedic Society and confirmed on a larger patients cohort

 

 

English - Français - Dutch

 

 

 

18 January 2022

 

 


TheraVet strengthens its sales organisation in France by signing an important distribution agreement for BIOCERA-VET®

 

 

English - Français - Dutch

 

 

 

16 December 2021

 

 

 

TheraVet is strengthening its corporate governance with the appointment of three new independent board members

 

 

English - Français - Dutch

 

 

 

09 December 2021

 

 

 

Commercial launch of BIOCERA-VET® for canine osteosarcoma in Belgium, France and The Netherlands

 


English - Français - Dutch

 

 

 

22 November 2021

 

 

 

TheraVet broadens significantly its BIOCERA-VET® product line through major distribution and research agreements

 

 

 

English - Français - Dutch

 

 

 

15 November 2021

 

 


TheraVet announces positive safety and efficacy results for BIOCERA-VET® in canine osteosarcoma

 

 


26 October 2021

 

 

 

First patients treated with BIOCERA-VET® Bone Surgery in the United States of America

 

 

 

21 October 2021

 

 


Commercial Launch of BIOCERA-VET® in France and The Netherlands

 

 

 

English - Français - Dutch

 

 

 

02 July 2021

 

 

 

TheraVet extends the use of BIOCERA-VET® to new curative approach of osteosarcoma in dogs

 

 

 

English - Français - Dutch

 

 

 

27 April 2021

 

 

 

BIOCERA-VET®: a promising alternative to autologous bone graft in canine arthrodesis

 

 

 

English - Français - Dutch

 

 

 

01 April 2021

 

 

 

TheraVet announces the commercial launch of BIOCERA-VET®

 

 

 

17 November 2020

 

 

 

TheraVet launches a prospective multicentric clinical trial in canine osteosarcoma

 

 

 

English - Français

 

 

 

For more press releases, click here
This website uses cookies The website of TheraVet SA uses functional cookies. In case of analysing our traffic or advertising, we also place cookies that share information about your use of our site with our analytics partners, our social media and advertising partners, who may combine it with other information that you’ve provided to them or that they’ve collected from your use of their services.
Show details Hide details
Allow selection Allow all cookies